PROVECTUS BIOPHARMACEUTICALS, INC.
Income Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2015 | FY2014 | FY2013 | FY2012 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $336.1K | $617.1K | $557.7K | $989.0K | $0 | $0 | $0 | $0 |
| Cost of Revenue | — | — | — | — | — | — | — | — |
| Gross Profit | — | — | — | — | — | — | — | — |
| Gross Margin | — | — | — | — | — | — | — | — |
| Operating Expenses | ||||||||
| Research & Development | $1.9M | $2.1M | $1.7M | $2.4M | $11.4M | $5.8M | $3.6M | $5.0M |
| SG&A Expense | $3.7M | $3.1M | $1.7M | $2.0M | $13.3M | $11.0M | $8.8M | $8.7M |
| Operating Income | $-5.3M | $-4.5M | $-2.9M | $-3.4M | $-24.7M | $-12.6M | $-13.0M | $-14.3M |
| Operating Margin | -1,575.3% | -734.4% | -520.2% | -346.6% | — | — | — | — |
| Interest Expense | $5.3K | $13.6K | $5.7K | $3.4K | — | — | — | — |
| Pretax Income | $-5.5M | $-4.8M | $-3.1M | $-3.6M | — | — | — | — |
| Income Tax Expense | — | — | — | — | $0 | $0 | $0 | $0 |
| Net Income | $-5.4M | $-4.7M | $-3.1M | $-3.6M | $-24.5M | $-10.2M | $-27.7M | $-12.6M |
| Net Margin | -1,615.8% | -766.9% | -556.2% | -359.4% | — | — | — | — |
| EPS (Basic) | $-0.01 | $-0.01 | $-0.01 | $-0.01 | $-0.13 | $-0.06 | $-0.22 | $-0.11 |
| EPS (Diluted) | $-0.01 | $-0.01 | $-0.01 | $-0.01 | $-0.13 | $-0.06 | $-0.22 | $-0.11 |
| Shares Outstanding (Basic) | 420.3M | 419.8M | 419.5M | 419.5M | 205.0M | 184.8M | 159.8M | 118.4M |
| Shares Outstanding (Diluted) | 420.3M | 419.8M | 419.5M | 419.5M | 205.0M | 184.8M | 159.8M | 118.4M |
| Dividends Per Share | — | — | — | — | — | — | — | — |